JuliaWattacherilMDMPH

Hepatology & Liver Transplantation

Associate Professor, Medicine, Columbia University Medical Center - NY Presbyterian

Overview of Dr. Wattacheril

Dr. Julia Wattacheril is a gastroenterologist in New York, NY and is affiliated with multiple hospitals in the area, including New York-Presbyterian Hospital, New York-Presbyterian Hospital, and NewYork-Presbyterian/Columbia University Irving Medical Center. She received her medical degree from Baylor College of Medicine and has been in practice 13 years. She is one of 302 doctors at New York-Presbyterian Hospital and one of 115 doctors at NewYork-Presbyterian/Columbia University Irving Medical Center who specialize in Gastroenterology. She also speaks multiple languages, including Spanish. She has more than 30 publications and over 500 citings.

Office
622 W 168th St
New York, NY 10032
Book by Phone+1(412) 368-5989

Fax+1 212-305-4343

Education & Training

New York Presbyterian Hospital (Columbia Campus)Fellowship, Transplant Hepatology, 2010 - 2011
Vanderbilt University Medical CenterFellowship, Gastroenterology, 2007 - 2010
Baylor College of MedicineResidency, Internal Medicine, 2004 - 2007
Baylor College of MedicineClass of 2004

Certifications & Licensure

TX State Medical License 2008 - 2026
NY State Medical License 2010 - 2025
CT State Medical License 2020 - 2020
TN State Medical License 2007 - 2015
American Board of Internal Medicine Gastroenterology
American Board of Internal Medicine Transplant Hepatology

Clinical Trials

Clinical Trial to Evaluation the Safety and Efficacy of GR-MD-02 for the Treatment of Liver Fibrosis and Resultant Portal Hypertension in Patients With Nash Cirrhosis Start of enrollment: 2015 Jun 01
Completed
Phase 2
Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment Start of enrollment: 2015 Sep 22
Terminated
Phase 3
Emricasan, a Caspase Inhibitor, for Evaluation in Subjects With Non-Alcoholic Steatohepatitis (NASH) Fibrosis Start of enrollment: 2016 Jan 26
Completed
Phase 2
Phase 3 Study to Evaluate the Efficacy and Safety of Elafibranor Versus Placebo in Patients With Nonalcoholic Steatohepatitis (NASH) Start of enrollment: 2016 Mar 01
Terminated
Phase 3
Study to Evaluate Safety, Tolerability and Efficacy of Saroglitazar Mg in Patients With Primary Biliary Cholangitis Start of enrollment: 2017 Aug 18
Completed
Phase 2
Join now to see all

Publications & Presentations

PubMed

91 citations
Impact of obeticholic acid on the lipoprotein profile in patients with non-alcoholic steatohepatitis.
Mohammad S. Siddiqui, Mark L. Van Natta, Margery A. Connelly, Raj Vuppalanchi, Brent A. Neuschwander-Tetri
Journal of Hepatology. 2020-01-01
13 citations
Health Disparities in Screening, Diagnosis, and Treatment of Hepatocellular Carcinoma
Averill Guo, Sydney Pomenti, Julia Wattacheril
Clinical Liver Disease. 2021-05-01
32 citations
AGA Clinical Practice Update on the Role of Noninvasive Biomarkers in the Evaluation and Management of Nonalcoholic Fatty Liver Disease: Expert Review.
Julia J Wattacheril, Manal F Abdelmalek, Joseph K Lim, Arun J Sanyal
Gastroenterology. 2023-10-01

Press Mentions

Cooking and Coping: Making Brooklyn Blackout Cake with Julia Wattacheril in New York CityMarch 31st, 2020
NASH Is the 21st Century’s Looming Public Health ThreatJanuary 30th, 2016